Icosavax to Participate in the William Blair Biotech Focus Conference
July 06 2022 - 4:05PM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases and a vision
of creating pan-respiratory vaccines for older adults, today
announced that the company will participate in the William Blair
Biotech Focus Conference taking place from July 12-13, 2022, in New
York.
Adam Simpson, Chief Executive Officer of
Icosavax, will also participate in a pre-recorded analyst led
fireside chat that will be available for replay from 9:00 a.m. ET
on July 11, 2022.
Interested parties can access the live audio
webcast for this conference from the Investor Relations section of
the company's website at www.icosavax.com. The webcast replay will
be available after the conclusion of the panel discussion for
approximately 30 days.
About Icosavax
Icosavax is a biopharmaceutical company
leveraging its innovative VLP platform technology to develop
vaccines against infectious diseases, with an initial focus on
life-threatening respiratory diseases and a vision for combination
and pan-respiratory vaccines. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s pipeline includes vaccine candidates targeting
respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and
an emerging program in influenza. Icosavax was formed in 2017 to
advance the breakthrough VLP technology from the Institute for
Protein Design at the University of Washington with the goal to
discover, develop, and commercialize vaccines against infectious
diseases. Icosavax is located in Seattle.
For more information,
visit www.icosavax.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are forward-looking
statements. The forward-looking statements are based on the
company’s current beliefs and expectations and include, but are not
limited to: the company’s expectation regarding the prophylactic
and commercial potential of its vaccine product candidates and its
platform technology. Actual results may differ from those set forth
in this press release due to the risks and uncertainties inherent
in the company’s business, including, without limitation: the early
stage of the company’s development efforts; the company’s approach
to the development of vaccine candidates, which is a novel and
unproven approach; unexpected adverse side effects or inadequate
immunogenicity or efficacy of the company’s vaccine candidates that
may limit their development, regulatory approval, and/or
commercialization; and other risks described in the company’s
filings with the Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in the company’s
quarterly report on Form 10-Q for the quarter ended March
31, 2022 and any subsequent filings with the SEC. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and the company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Media Contact: Jessica
Yingling, Ph.D. Little Dog Communications Inc.
jessica@litldog.com858.344.8091
Investor Contact:Laurence
WattsGilmartin Group, LLClaurence@gilmartinir.com619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Sep 2023 to Sep 2024